Monoclonal antibodies targeting DR4 and DR5 have been proven to be clinically effective for cancer treatment because they can selectively bind to specific antigens and have longer half life as compared to rhTRAIL ligands (188). The gene discussed is TNFRSF10A; the disease is cancer.